6th mRNA-Based Therapeutics Summit

From recent acquisitions - including Eli Lilly and Orna, BMS and Orbital, AbbVie and Capstan and BioNTech and CureVac - the mRNA landscape is evolving fast, with assets in in vivo CAR-T, gene editing, and cancer immunotherapies advancing toward clinical validation and potential commercial reality.
 
 
With science innovation at the core of the momentum, the 6th mRNA‑Based Therapeutics Summit returns to Boston this summer as the world's flagship meeting for the mRNA community. Bringing together 350+ global leaders - from pharma powerhouses to trailblazing biotech start-ups including Moderna, Pfizer, AstraZeneca, Sanofi, ParcelBio, CaVos Therapeutics, Kernal Biologics and more - the summit delivers exclusive breakthroughs, strategic insights, and collaboration opportunities that are shaping the conversation and future of mRNA technology.
 
 
With a revitalized three-track agenda covering Discovery, Pre-Clinical and Clinical Development, and Manufacturing and CMC, plus two brand-new focus days on AI-Driven mRNA Design and Next-Gen Delivery Technologies, this forum reaffirms its position as the go-to hub for uniting top decision makers, showcasing scientific excellence, partnership building, and pipeline acceleration.
 
 
Join with your peers and power the next wave of mRNA therapies and tools to combat all diseases.